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The molecular basis of sarcoma remains poorly understood. However, recent studies have begun to uncover some of the
molecular pathways involved in sarcomagenesis. The chemokine receptor CXCR4 has been implicated in sarcoma development
and has been found to be a prognostic marker for poor clinical outcome. There is growing evidence that overexpression of
CXCR4 plays a signiﬁcant role in development of metastatic disease, especially in directing tumor cells towards the preferential
sites of metastases in sarcoma, lung and bone. Although further investigation is necessary to validate these pathways, there is
potential for clinical application, particularly in the use of pharmacologic inhibitors of CXCR4 as means of preventing sarcoma
metastasis.
1.Introduction
Sarcomas are relatively rare tumors of mesenchymal origin,
accounting for less than 1% of malignancies [1, 2]. The
American Cancer Society (ACS) estimates that there will be
10,500 new cases of soft tissue sarcoma in 2010 [1]. An esti-
mated 3,920 patientswill die in2010 from sarcoma inthe US
[1]. In addition to their rarity, sarcomas are a heterogeneous
group of malignancies, with over 50 diﬀerent histologic
subtypes with highly variable microscopic appearance and
clinicalbehavior [3]. The combination ofrarity and diversity
has made scientiﬁc investigation into the molecular basis of
sarcomas challenging [2]. Indeed, even the cell of origin in
sarcomas remains unidentiﬁed and a subject of controversy
[4]. However, recent studies have started to uncover some
of the molecular markers and pathways that contribute to
human sarcomagenesis [4]. Among these recent discoveries
is the role that the chemokine receptor CXCR4 plays in the
pathogenesis of several subtypes of sarcoma. In this paper,
we will review the literature on the function of CXCR4 in
human sarcomagenesis.
2.Chemokine Receptor4 (CXCR4)
Chemokinesare8to12kDapeptidesthatfunctionincelldif-
ferentiation,migration,andtraﬃckingbyactingaschemoat-
tractant cytokines [5]. There are four groups of chemokine
receptors: C, CC, CXC, and CX3C. Chemokine receptor
4 (CXCR4) is a seven-transmembrane G protein-coupled
chemokine receptor [6]. CXCR4 is normally expressed on
T-lymphocytes, B-lymphocytes, monocytes, macrophages,
neutrophils, eosinophils, in addition to being present in
brain, lung, colon, heart, kidney, and liver cells [5]. CXCR4
is also expressed on astrocytes, neuronal cells, and smooth
muscle progenitors [5]. CXCR4 is also the chemokine recep-
tor most commonly expressed in tumor cells, with increased
expression in melanoma, breast, ovarian, gastric, prostate,
colorectal, and lung cancer [7–10]. High levels of CXCR4
have been shown to correlate with the presence of metastatic
disease in a wide variety of malignancies, including breast,
prostate, lung, colorectal cancer, melanoma, and neurob-
lastoma [8, 10–16]. CXCR4 has also been demonstrated
to be involved in cell migration and invasion, as well as
angiogenesis.2 Sarcoma
The activation of CXCR4 by its ligand, CXCL12, initiates
multiple intracellular signaling cascades [5]. CXCL12, also
known as stromal cell-derived factor-1 (SDF-1), is a home-
ostatic chemokine. CXCL12’s major function is in regulating
hematopoieticcelltraﬃcking and secondary lymphoidtissue
architecture. In malignancy, high expression of CXCL12 has
been found in lung and bone, tissues that are preferential
sites for certain malignancies, such as breast cancer.
3.Osteosarcoma
Osteosarcoma, also known as osteogenic sarcoma, is the
most common primary bone malignancy [4]. CXCR4 is
expressed in 67% of osteosarcomas, with high levels of
expression correlating with decreased overall survival, event-
free survival, and metastasis-free survival [17]. Survival is
only 10% in tumor samples that express CXCR4 mRNA,
compared to 90% survival in tumor samples that do
not express CXCR4 mRNA. CXCR4 expression level also
correlates with the presence of metastasis at diagnosis [17].
Human osteosarcoma cell lines also have been found to
express high levels of CXCL12 [17].
Osteosarcoma preferentially metastasizes to lung and
bone, tissues with high levelsof CXCL12 [10]. Osteosarcoma
cells expressing CXCR4 migrate towards a CXCL12 gradient
[18]. Adhesion of osteosarcoma to endothelial and bone
marrow stromal cells is also promoted by CXCL12. In
addition, there is a signiﬁcant correlation in osteosarcoma
between CXCR4 and expression of vascular endothelial
growth factor (VEGF), a critical mediator of angiogenesis
and tumor proliferation [19].
The role of CXCR4 in osteosarcoma metastasis has been
further validated in animal models. The T134 peptide, a
CXCR4 inhibitor, was found to prevent the development
of lung metastasis after the injection of osteosarcoma cells
in a mouse model [18]. In another study, administration
of CTCE-9908, also a CXCR4 inhibitor, resulted in a 50%
decrease in the number of metastases in mice injected with
osteosarcoma cells [20].
4.Rhabdomyosarcoma
Rhabdomyosarcoma (RMS) is the most common soft tissue
malignancy in children [21]. CXCR4 is highly expressed on
the surface of RMS cells, with higher expression in the more
clinicallyaggressivealveolarsubtypeofRMScomparedtothe
embryonal subtype [21, 22]. High CXCR4 expression also
correlates with unfavorable primary sites, advanced stage,
marrow involvement, decreased overall survival, and event-
free survival in RMS [23].
CXCL12 has no eﬀect on the proliferation or survival
of RMS cells, but does stimulate processes related to cell
invasion and metastasis [22]. CXCL12 increases adhesion of
RMScellstoendothelium.RMScellsalsofollow adirectional
chemotaxis towards bone marrow stroma, a CXCL12-rich
environment, which may indicate a role of CXCR4 in ten-
dency of RMS to preferentially metastasize to bone marrow
[21, 22]. However, CXCL12 did not increase the survival of
RMS cells exposed to radiation or chemotherapy, indicating
that CXCR4 may not play a role in the development of
treatment resistance [24].
5.Chondrosarcoma
Chondrosarcoma is the second most common primary bone
malignancy, after osteosarcoma [25]. CXCR4 and CXCL12
expressions have been found to be increased in both chon-
drosarcoma tissue and cell lines [26], with the expression of
CXCR4 correlating with tumor grade. CXCR4 signaling reg-
ulatestheexpression ofmatrix metalloproteinase 1(MMP1),
a marker of chondrosarcoma tissue invasion, metastasis, and
poor prognosis [25]. In addition, CXCR4 signaling appears
to partially mediate hypoxia-induced increases in MMP1
expression [25].
6.Ewing’s Sarcoma
Ewing’s sarcomas are poorly diﬀerentiated tumors and have
highmetastaticpotential[4,27].Asubset ofEwing’ssarcoma
tumors and cell lines predominately express CXCR4. High
expression of CXCR4 correlates with metastatic Ewing’s
sarcoma and with poor patient survival [27]. Also, CXCL12
has been demonstrated to be a potent stimulator of invasion
by Ewing’s sarcoma cells [28].
7.Malignant FibrousHistiocytoma
Malignant ﬁbroushistiocytoma (MFH),also termed ashigh-
grade undiﬀerentiated pleomorphic sarcoma, is one of the
highest-grade soft tissue sarcomas [4]. CXCR4 expression
has been shown to be upregulated in MFH tumor cell lines
[29].
8.Other SoftTissueSarcomas
In a heterogeneous group of malignant nonround cell
tumors,whichincludedsynovial sarcoma,malignantperiph-
eral nerve sheath tumor, leiomyosarcoma, MFH, liposar-
coma, ﬁbrosarcoma, angiosarcoma, clear cell sarcoma,
epithelioid sarcoma, osteosarcoma, and chondrosarcoma,
high CXCR4 mRNA expression was an independent predic-
tor of poor prognosis by univariate and Cox multivariate
analysis[30].Therewasalsoasigniﬁcantcorrelationbetween
CXCR4 and expression of VEGF in this group of soft tissue
sarcomas [30].
9.CXCR4Inhibition
Because of the wealth of evidence implicating CXCR4’s role
in metastatic disease for a variety of malignancies, CXCR4
inhibition has been investigated for its potential for clinical
application in cancer therapy. Plerixafor (AMD3100) was
initially discovered as an anti-HIV agent and later found to
be a potent selective inhibitor of CXCR4 [31]. Recently, it
has been utilized in multiple myeloma and non-Hodgkin’s
lymphoma as a hematopoietic stem cell mobilizer [32].Sarcoma 3
The use of plerixafor as a chemotherapeutic agent has
been suggested for nonhematologic malignancies, including
glioblastoma, various gastrointestinal cancers, melanoma,
and lung cancer [14, 20, 33, 34].
In regards to CXCR4 inhibition for sarcoma, as men-
tioned previously, CXCR4 inhibitors have been validated
in two animal models of osteosarcoma metastasis. The
CXCR4 inhibitors T134 peptide and CTCE-9908 have both
been shown to decrease or prevent the development the
osteosarcoma metastases in mice [18, 20]. Also, inhibition
of CXCR4 by plerixafor resulted in decreased directional cell
migration of a rhabdomyosarcoma cell line [21].
10.Summary
CXCR4appearstobeausefulprognosticmarkerformultiple
histologic subtypes of soft tissue sarcoma. High expression
levels of CXCR4 are correlated with poor outcomes and also
predictmetastatic disease. There isevidencethat CXCR4and
its ligand, CXCL12, play a critical role in the preferential
targeting of sarcoma metastases towards lung and bone.
Finally, in vivo data indicate the potential of CXCR4 as
a target for chemotherapy agents and the possible use
of CXCR4 inhibitors in preventing the development of
metastasis from sarcomas. Further studies will be necessary
to translate this potential into application in the form of
clinical trials.
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